国家医保局发布关于2025年国家基本医保目录及商保创新药目录调整通过形式审查的申报药品专家评审阶段性结果查询的公告

Core Points - The National Healthcare Security Administration (NHSA) has announced the results of the expert review phase for the 2025 National Basic Medical Insurance (BMI) and commercial health insurance innovative drug directory adjustments [1][2] - The review process was conducted with the support of relevant departments, applicant companies, and expert reviewers, following the established adjustment work plan [1] Group 1 - The expert review results include categories such as "proposed simple renewal," "proposed renegotiation renewal," "proposed negotiation addition," "proposed competitive addition," and "proposed price negotiation" for the drugs [1][2] - Companies can check the review results by logging into the NHSA service platform and accessing the "2025 Basic Medical Insurance Directory and Commercial Health Insurance Innovative Drug Directory Adjustment" module [1] - Companies must submit the required confirmation letters and qualification materials by September 23, 2025, to the NHSA [1][2] Group 2 - For drugs confirmed for negotiation, competitive bidding, and price negotiation, companies are required to download and submit the corresponding material templates by September 30, 2025 [2] - The review results indicate that drugs listed as "proposed negotiation addition," "proposed competitive addition," and "proposed price negotiation" are eligible for negotiation but do not guarantee inclusion in the final directories [2] - A communication meeting for companies involved in negotiations and bidding will be held in Beijing, with details to be announced later [2]